Home » Stocks » QDEL

Quidel Corporation (QDEL)

Stock Price: $188.00 USD 7.24 (4.01%)
Updated November 27, 1:00 PM EST - Market closed
Pre-market: $191.37 +3.37 (1.79%) Nov 30, 9:08 AM

Stock Price Chart

Key Info

Market Cap 7.91B
Revenue (ttm) 1.00B
Net Income (ttm) 370.78M
Shares Out 42.07M
EPS (ttm) 8.54
PE Ratio 22.01
Forward PE 20.33
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $188.00
Previous Close $180.76
Change ($) 7.24
Change (%) 4.01%
Day's Open 183.00
Day's Range 178.90 - 189.88
Day's Volume 533,837
52-Week Range 67.73 - 301.96

More Stats

Market Cap 7.91B
Enterprise Value 7.95B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 42.07M
Float n/a
EPS (basic) 8.83
EPS (diluted) 8.54
FCF / Share 4.60
Dividend n/a
Dividend Yield n/a
Earnings Yield 4.54%
FCF Yield 2.45%
Payout Ratio n/a
Shares Short 2.51M
Short Ratio 2.65
Short % of Float n/a
Beta 0.84
PE Ratio 22.01
Forward PE 20.33
P/FCF Ratio 40.82
PS Ratio 7.87
PB Ratio 8.95
Revenue 1.00B
Operating Income 478.31M
Net Income 370.78M
Free Cash Flow 193.73M
Net Cash -38.95M
Net Cash / Share -0.93
Gross Margin 31.93%
Operating Margin 47.61%
Profit Margin 36.90%
FCF Margin 19.28%
ROA 28.72%
ROE 53.60%
ROIC 109.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$285.25*
(51.73% upside)
Low
175
Current: $188.00
High
371
Target: 285.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue535522278192196184177156159113
Revenue Growth2.41%88.05%44.96%-2.31%6.5%3.85%13.86%-1.8%39.94%-
Gross Profit32131615611211811011094.4695.7460.73
Operating Income92.7295.939.55-4.442.74-9.214.849.6913.74-15.29
Net Income72.9274.18-8.17-13.81-6.08-7.077.394.997.63-11.27
Shares Outstanding40.8638.0033.7332.7134.1034.4533.8433.0732.9028.58
Earnings Per Share1.731.86-0.24-0.42-0.18-0.210.210.150.23-0.39
EPS Growth-6.99%-----40%-34.78%--
Operating Cash Flow13413627.7111.8236.8835.6925.6819.6347.54-10.21
Capital Expenditures-27.23115-17.51-11.91-17.03-11.24-22.50-27.60-21.14-10.48
Free Cash Flow10725110.20-0.0919.8524.453.18-7.9726.41-20.69
Cash & Equivalents52.7843.7036.091701922049.3614.8661.336.79
Total Debt1121083971441481435.5710.9548.2880.05
Net Cash / Debt-59.53-63.87-36125.1743.6260.943.793.9113.06-73.27
Assets911806935388407447271242279215
Liabilities35138170818818820247.7142.3293.51102
Book Value560426227201219245224200185113
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Quidel Corporation
Country United States
Employees 1,250
CEO Douglas C. Bryant

Stock Information

Ticker Symbol QDEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: QDEL

Description

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.